REFERENCES
1. Frisoni GB, Hansson O, Nichols E, et al. New landscape of the diagnosis of Alzheimer’s disease. Lancet. 2025;406:1389-407.
2. Reiss AB, Housny M, Gulkarov S, et al. Role of apolipoprotein E in Alzheimer’s disease pathogenesis, prognosis and treatment. Discov Med. 2024;36:1917-32.
3. Testo AA, Roundy G, Dumas JA. Cognitive decline in Alzheimer’s disease. In: Kidd EJ, Newhouse PA, Editors. Neurobiology of Alzheimer’s disease. Cham: Springer Nature Switzerland; 2025. pp. 181-95.
5. Soni U, Singh K, Jain D, Pujari R. Exploring Alzheimer’s disease treatment: Established therapies and novel strategies for future care. Eur J Pharmacol. 2025;998:177520.
6. Chew CS, Lee JY, Ng KY, Koh RY, Chye SM. Resilience mechanisms underlying Alzheimer’s disease. Metab Brain Dis. 2025;40:86.
7. Zhang J, Kong G, Yang J, Pang L, Li X. Pathological mechanisms and treatment progression of Alzheimer’s disease. Eur J Med Res. 2025;30:625.
8. Beder N, Belkhelfa M, Leklou H. Involvement of inflammasomes in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2024;102:11-29.
9. Ziar R, Tesar PJ, Clayton BLL. Astrocyte and oligodendrocyte pathology in Alzheimer’s disease. Neurotherapeutics. 2025;22:e00540.
10. Wang C, Wang S, Xue Y, et al. Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system. Nat Biotechnol. 2025;43:1783-9.
11. Han J, Zhang X, Kang L, Guan J. Extracellular vesicles as therapeutic modulators of neuroinflammation in Alzheimer’s disease: a focus on signaling mechanisms. J Neuroinflammation. 2025;22:120.
12. Yin T, Liu Y, Ji W, et al. Engineered mesenchymal stem cell-derived extracellular vesicles: a state-of-the-art multifunctional weapon against Alzheimer’s disease. Theranostics. 2023;13:1264-85.
13. Jeppesen DK, Zhang Q, Coffey RJ. Extracellular vesicles and nanoparticles at a glance. J Cell Sci. 2024;137:jcs260201.
14. Dhapola R, Kumari S, Sharma P, et al. Deciphering molecular and signaling pathways of extracellular vesicles-based therapeutics for Alzheimer’s disease. Mol Neurobiol. 2025;62:15430-49.
15. Welsh JA, Goberdhan DC, O’Driscoll L, Théry C, Witwer KW. MISEV2023: an updated guide to EV research and applications. J Extracell Vesicles. 2024;13:e12416.
16. Welsh JA, Goberdhan DCI, O’Driscoll L, et al. ; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
17. Gao G, Li C, Ma Y, et al. Neural stem cell-derived extracellular vesicles mitigate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Signal Transduct Target Ther. 2023;8:228.
18. Zhang W, Uyemura R, Zhong K, Guo R, Zhong L. Current advances and future perspectives on mesenchymal stem cell-derived extracellular vesicles in Alzheimer’s disease. Aging Dis. 2024;15:2015-27.
19. Rather HA, Almousa S, Craft S, Deep G. Therapeutic efficacy and promise of stem cell-derived extracellular vesicles in Alzheimer’s disease and other aging-related disorders. Ageing Res Rev. 2023;92:102088.
20. Zhai Y, Gao F, Shi S, et al. Noninvasive optogenetics realized by iPSC-derived tentacled carrier in Alzheimer’s disease treatment. Adv Mater. 2025;37:e2419768.
21. Liu T, Rong Z, Li J, Wu H, Wei J. Three-dimensional interactive network: Mitochondrial-metabolic-calcium homeostasis driving Alzheimer’s disease. Genes Dis. 2026;13:101846.
22. Takahashi T, Muguruma K. Alzheimer’s disease: from pathogenesis to emerging therapeutic targets. J Clin Med. 2026;15:2357.
23. Ferrari-Souza JP, Povala G, Rahmouni N, et al. Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease. Nat Neurosci. 2026;29:81-7.
24. Amelimojarad M, Amelimojarad M, Cui X. The emerging role of brain neuroinflammatory responses in Alzheimer’s disease. Front Aging Neurosci. 2024;16:1391517.
25. Dash UC, Bhol NK, Swain SK, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications. Acta Pharm Sin B. 2025;15:15-34.
26. Kemna RE, Kueck PJ, Honea R, et al. Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer’s disease. Alzheimers Dement. 2025;21:e70390.
27. Lattmann R, Vockert N, Bernal J, et al. Dysfunction of the episodic memory network in the Alzheimer’s disease cascade. Nat Commun. 2026;17:3578.
28. Jamann N, Montijn JS, Petersen N, et al. Layer 5 myelination gates corticothalamic coincidence detection. Nat Commun. 2025;16:10922.
29. Schumacher J, Ray NJ, Hamilton CA, et al. Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease. Brain. 2022;145:1773-84.
30. Carnevale LN, Banerjee P, Zhang X, et al. Redox regulation of neuroinflammatory pathways contributes to damage in Alzheimer’s disease brain. Cell Chem Biol. 2026;Epub ahead of print.
31. Yu Y, Yu S, Battaglia G, Tian X. Amyloid-β in Alzheimer’s disease: structure, toxicity, distribution, treatment, and prospects. Ibrain. 2024;10:266-89.
32. Yu Y, Xiao W, Ma Z, Yi X, Zhong T, Li Z. Circulatory extracellular vesicles transport complement C1q for promoting neuronal amyloid-β production in Alzheimer’s disease. J Neuroinflammation. 2025;22:209.
33. Sasmita AO, Depp C. A question of origins: non-neuronal sources of Amyloid-β. Neurosci Bull. 2026;42:1126-50.
34. Pacheco-Quinto J, Clausen D, Pérez-González R, et al. Intracellular metalloprotease activity controls intraneuronal Aβ aggregation and limits secretion of Aβ via exosomes. FASEB J. 2019;33:3758-71.
35. Wang C, Yang Y, Zhang X, et al. Secreted endogenous macrosomes reduce Aβ burden and ameliorate Alzheimer’s disease. Sci Adv. 2023;9:eade0293.
36. Pineda-Lopez L, Aguillon D, Villar-Vesga J, et al. Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer’s disease. Alzheimers Dement. 2026;22:e71148.
37. Chinnathambi S, Kumarappan M, Malik S, Velmurugan G, Chandrashekar M. Neuron-derived extracellular vesicle-based diagnostics for Tau and Alzheimer’s disease. Brain Network Disorders. 2025;1:150-66.
38. Peng D, Liu T, Lu H, et al. Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer’s disease phenotypes. Theranostics. 2024;14:7623-44.
39. Liu S, Fan M, Xu JX, et al. Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology. J Neuroinflammation. 2022;19:35.
40. Ma X, Huang M, Zheng M, et al. ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer’s disease. J Control Release. 2020;327:688-702.
41. Li M, Chen S, Guo R, et al. Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy. Signal Transduct Target Ther. 2025;10:360.
42. Xie H, Wu F, Mao J, et al. The role of microglia in neurological diseases with involvement of extracellular vesicles. Neurobiol Dis. 2024;202:106700.
43. Cone AS, Yuan X, Sun L, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Theranostics. 2021;11:8129-42.
44. Apodaca LA, Baddour AAD, Garcia C Jr, et al. Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease. Alzheimers Res Ther. 2021;13:57.
45. Huber CC, Callegari EA, Paez MD, Romanova S, Wang H. Heat shock-induced extracellular vesicles derived from neural stem cells confer marked neuroprotection against oxidative stress and Amyloid-β-Caused neurotoxicity. Mol Neurobiol. 2022;59:7404-12.
46. Li B, Chen Y, Zhou Y, et al. Neural stem cell-derived exosomes promote mitochondrial biogenesis and restore abnormal protein distribution in a mouse model of Alzheimer’s disease. Neural Regen Res. 2024;19:1593-601.
47. Li N, Shu J, Yang X, Wei W, Yan A. Exosomes derived from M2 microglia cells attenuates neuronal impairment and mitochondrial dysfunction in Alzheimer’s disease through the PINK1/Parkin pathway. Front Cell Neurosci. 2022;16:874102.
48. Pourhadi M, Zali H, Ghasemi R, Faizi M, Mojab F, Soufi Zomorrod M. Restoring synaptic function: how intranasal delivery of 3D-cultured hUSSC exosomes improve learning and memory deficits in Alzheimer’s disease. Mol Neurobiol. 2024;61:3724-41.
49. Kwon H, Lee EH, Park SY, et al. Lactobacillus-derived extracellular vesicles counteract Aβ42-induced abnormal transcriptional changes through the upregulation of MeCP2 and Sirt1 and improve Aβ pathology in Tg-APP/PS1 mice. Exp Mol Med. 2023;55:2067-82.
50. Calzoni E, Cusumano G, Bertoldi A, et al. Rhubarb-derived extracellular vesicles mitigate oxidative stress and metabolic dysfunction in an Alzheimer’s cellular model. Nutrients. 2025;17:3771.
51. Chinnathambi S, Rangappa N, Chandrashekar M. Internalization of extracellular Tau oligomers in Alzheimer’s disease. Elsevier; 2025. pp. 1-29.
52. Singh M, Ali H, Renuka Jyothi S, et al. Tau proteins and senescent cells: targeting aging pathways in Alzheimer’s disease. Brain Res. 2024;1844:149165.
53. Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584-93.
54. Jain N, Ulrich JD. TREM2 and microglia exosomes: a potential highway for pathological tau. Mol Neurodegener. 2022;17:73.
55. Penney J, Ralvenius WT, Loon A, et al. iPSC-derived microglia carrying the TREM2 R47H/+ mutation are proinflammatory and promote synapse loss. Glia. 2024;72:452-69.
56. Fowler SL, Behr TS, Turkes E, et al. Tau filaments are tethered within brain extracellular vesicles in Alzheimer’s disease. Nat Neurosci. 2025;28:40-8.
57. Zhu B, Liu Y, Hwang S, et al. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol Neurodegener. 2022;17:58.
58. Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y. TREM2, microglia, and Alzheimer’s disease. Mech Ageing Dev. 2021;195:111438.
59. Lan G, Li A, Gonzalez-Ortiz F, et al. Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease. Mol Psychiatry. 2025;30:3988-97.
60. Song Z, Xie X, Chen Y, et al. Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflammation in Alzheimer’s disease. Immunity. 2025;58:2574-92.e9.
61. Wang J, Wu J, Ma X, et al. A double-edged sword: exploring the neuroprotective/damaging mechanisms of complement activation in Alzheimer’s disease. Aging Health Res. 2025;5:100267.
62. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. 2019;8:1605.
63. Yu M, Ma H, Lai X, Wu J, Shen M, Yan J. Stem cell extracellular vesicles: a new dawn for anti-inflammatory treatment of neurodegenerative diseases. Front Aging Neurosci. 2025;17:1592578.
64. Zhang J, He S, Xiao Q, et al. Engineered mesenchymal stem cell-derived extracellular vesicles overexpressing miR-146a alleviate neuroinflammation in Alzheimer’s disease. Neural Regen Res. 2026;21:4989-99.
65. Losurdo M, Pedrazzoli M, D’Agostino C, et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer’s disease. Stem Cells Transl Med. 2020;9:1068-84.
66. Xu X, Fan SS, Li J, et al. Integrated multi-omics analysis and cross-model validation reveal mitochondrial signatures in Alzheimer’s disease. CNS Neurosci Ther. 2025;31:e70634.
67. Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis. Alzheimers Dement. 2023;19:333-42.
68. D’Alessandro MCB, Kanaan S, Geller M, Praticò D, Daher JPL. Mitochondrial dysfunction in Alzheimer’s disease. Ageing Res Rev. 2025;107:102713.
69. Wang W, Qu Y, Li S, et al. Neuroprotective effects of curculigoside against Alzheimer’s disease via regulation oxidative stress mediated mitochondrial dysfunction in L-Glu-exposed HT22 cells and APP/PS1 mice. Food Sci Hum Wellness. 2023;12:1265-78.
70. Zhang Q, Li S, Chen H, et al. Reduction of oxidative stress and excitotoxicity by mesenchymal stem cell biomimetic Co-delivery system for cerebral ischemia-reperfusion injury treatment. Small. 2024;20:e2401045.
71. Huang T, Tong H, Zhou H, et al. ADSC-exosomes alleviate MTX-induced rat neuronal damage by activating Nrf2-ARE pathway. J Mol Neurosci. 2022;72:1334-44.
72. Santos MFD, Roxo C, Solá S. Oxidative-signaling in neural stem cell-mediated plasticity: implications for neurodegenerative diseases. Antioxidants. 2021;10:1088.
73. Gotoh S, Kawabori M, Yamaguchi S, et al. Intranasal administration of stem cell-derived exosome alleviates cognitive impairment against subarachnoid hemorrhage. Exp Neurol. 2025;386:115143.
74. Long Q, Upadhya D, Hattiangady B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci U S A. 2017;114:E3536-45.
75. Du B, Zou Q, Wang X, et al. Multi-targeted engineered hybrid exosomes as Aβ nanoscavengers and inflammatory modulators for multi-pathway intervention in Alzheimer’s disease. Biomaterials. 2025;322:123403.
76. Depp C, Sun T, Sasmita AO, et al. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease. Nature. 2023;618:349-57.
77. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9:211.
78. Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D. Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep. 2024;51:48.
79. Gaikwad S, Senapati S, Haque MA, Kayed R. Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer’s disease: evidence from clinical and preclinical studies. Alzheimers Dement. 2024;20:709-27.
80. Gallego-Rudolf J, Wiesman AI, Pichet Binette A, Villeneuve S, Baillet S; PREVENT-AD Research Group. Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults. Nat Neurosci. 2024;27:2130-7.
81. Sharma P, Kaur N, Vasal N, Solanki K, Sunkaria A. The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages. Ageing Res Rev. 2026;119:103168.
82. Zhu X, Zhang L, Qin C. Hub genes and diagnostic model associated with mitochondrial function in Alzheimer’s disease. Animal Model Exp Med. 2026;9:237-48.
83. Lee SH, Shin SM, Zhong P, et al. Reciprocal control of excitatory synapse numbers by Wnt and Wnt inhibitor PRR7 secreted on exosomes. Nat Commun. 2018;9:3434.
84. Wu C, Chen Z, Li J, et al. Engineered nanovesicles amplify the crosstalk between neurogenesis and angiogenesis for pro-regenerative niche construction. Nano Today. 2026;66:102932.
85. Micci MA, Krishnan B, Bishop E, et al. Hippocampal stem cells promotes synaptic resistance to the dysfunctional impact of amyloid beta oligomers via secreted exosomes. Mol Neurodegener. 2019;14:25.
86. Krämer-Albers EM, Werner HB. Mechanisms of axonal support by oligodendrocyte-derived extracellular vesicles. Nat Rev Neurosci. 2023;24:474-86.
87. Cai Y, Pinheiro-de-Sousa I, Slobodyanyuk M, et al. Myelin-axon interface vulnerability in Alzheimer’s disease revealed by subcellular proteomics and imaging of human and mouse brain. Nat Neurosci. 2025;28:1418-35.
88. Xu J, Wang R, Luo W, et al. Oligodendrocyte progenitor cell-specific delivery of lipid nanoparticles loaded with Olig2 synthetically modified messenger RNA for ischemic stroke therapy. Acta Biomater. 2024;174:297-313.
89. Sasmita AO, Depp C, Nazarenko T, et al. Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice. Nat Neurosci. 2024;27:1668-74.
90. Rajani RM, Ellingford R, Hellmuth M, et al. Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease. PLoS Biol. 2024;22:e3002727.
91. Fan L, Liu C, Chen X, et al. Exosomes-loaded electroconductive hydrogel synergistically promotes tissue repair after spinal cord injury via immunoregulation and enhancement of myelinated axon growth. Adv Sci. 2022;9:e2105586.
92. Zhang H, Xie XH, Xu SX, et al. Oligodendrocyte-derived exosomes-containing SIRT2 ameliorates depressive-like behaviors and restores hippocampal neurogenesis and synaptic plasticity via the AKT/GSK-3β pathway in depressed mice. CNS Neurosci Ther. 2024;30:e14661.
93. Ji XY, Guo YX, Wang LB, et al. Microglia-derived exosomes modulate myelin regeneration via miR-615-5p/MYRF axis. J Neuroinflammation. 2024;21:29.
94. Sun W, Chen Y, Yang Y, et al. Characteristics and transcriptomic analysis of cholinergic neurons derived from induced pluripotent stem cells with APP mutation in Alzheimer’s disease. J Alzheimers Dis. 2024;101:637-49.
95. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306:821-7.
96. Beier MT. Drug treatment for Alzheimer’s disease. Commentary: memantine treatment in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a randomized controlled trial. Consult Pharm. 2004;19:827-9.
97. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33:164-73.
98. Wang SS, Jia J, Wang Z. Mesenchymal stem cell-derived extracellular vesicles suppresses iNOS expression and ameliorates neural impairment in Alzheimer’s disease mice. J Alzheimers Dis. 2018;61:1005-13.
99. Bashirrohelleh MA, Bavarsad K, Khodadadi A, Shohan M, Asadirad A. Curcumin-enhanced stem cell exosomes: a novel approach to modulating neuroinflammation and improving cognitive function in a rat model of Alzheimer’s disease. Eur J Pharmacol. 2025;999:177695.
100. Jung YH, Jo HY, Kim DH, et al. Exosome-mediated mitochondrial regulation: a promising therapeutic tool for Alzheimer’s disease and Parkinson’s disease. Int J Nanomedicine. 2025;20:4903-17.
101. Kang X, Jiang L, Chen X, et al. Exosomes derived from hypoxic bone marrow mesenchymal stem cells rescue OGD-induced injury in neural cells by suppressing NLRP3 inflammasome-mediated pyroptosis. Exp Cell Res. 2021;405:112635.
102. Kim JE, Ji YE, Hwang HJ, et al. Engineered MSC-EVs loaded with BDNF-enhancing neuropeptides via a non-disruptive method enhance post-stroke neuroregeneration via intranasal delivery. J Nanobiotechnology. 2025;23:594.
103. Zhu C, Ren X, Liu C, Liu Y, Wang Y. Rbm8a regulates neurogenesis and reduces Alzheimer’s disease-associated pathology in the dentate gyrus of 5×FAD mice. Neural Regen Res. 2024;19:863-71.
104. Wei R, Zhang L, Hu W, Shang X, He Y, Zhang W. Zeb2/Axin2-enriched BMSC-derived exosomes promote post-stroke functional recovery by enhancing neurogenesis and neural plasticity. J Mol Neurosci. 2022;72:69-81.
105. Gao G, Li C, Zhu J, et al. Induced neural stem/progenitor cell-derived extracellular vesicles promote recovery post-stroke. Clin Transl Med. 2022;12:e936.
106. Zhu ZH, Jia F, Ahmed W, et al. Neural stem cell-derived exosome as a nano-sized carrier for BDNF delivery to a rat model of ischemic stroke. Neural Regen Res. 2023;18:404-9.
107. Natale F, Leone L, Rinaudo M, et al. Neural stem cell-derived extracellular vesicles counteract insulin resistance-induced senescence of neurogenic niche. Stem Cells. 2022;40:318-31.
108. Alves SM, Lisboa-Filho PN, Zilli Vieira CL, Piacenti-Silva M. Alzheimer’s disease and gut-brain axis: drosophila melanogaster as a model. Front Neurosci. 2025;19:1543826.
109. Hassan A, Huang Y, Mahjabina, et al. Emerging role of gut microbiota extracellular vesicle in neurodegenerative disorders and insights on their therapeutic management. IMetaOmics. 2024;1:e33.
110. Chen X, Li Q, Zhang W, et al. Akkermansia muciniphila-derived extracellular vesicles alleviate colitis-related cognitive impairment via tryptophan metabolic reprogramming of the gut-brain axis. Gut Microbes. 2026;18:2611546.
111. Ding L, Bian Q, Mou X, Chang X. Plant-derived exosome-like nanovesicles for CNS drug delivery and gut-brain axis modulation: a narrative review. Int J Nanomedicine. 2025;20:16093-123.
112. Xie J, Cools L, Van Imschoot G, et al. Helicobacter pylori-derived outer membrane vesicles contribute to Alzheimer’s disease pathogenesis via C3-C3aR signalling. J Extracell Vesicles. 2023;12:e12306.
113. Wang R, Zhang Y, Guo Y, et al. Plant-derived nanovesicles: promising therapeutics and drug delivery nanoplatforms for brain disorders. Fundam Res. 2025;5:830-50.
114. Wang S, Zhang Y, Zeng Y, et al. Plant-derived vesicle-like nanoparticles for immunomodulation: mechanisms and applications. Bioact Mater. 2026;55:171-204.
115. Cavaleri MP, Ardondi L, Vitali I, et al. Apple derived extracellular vesicles as positive modulators of glial inflammation and gut-brain axis signaling. Phytomedicine. 2026;156:158232.
116. Lieberman OJ, Douglas VC, LaHue SC. Reexamining cholinesterase inhibitors for the prevention and treatment of delirium in high-risk populations. Crit Care. 2023;27:129.
117. Zhao S, Duan L, Lv Z, et al. Extracellular vesicle-mediated precision delivery of paclitaxel activates mitophagy to promote repair after spinal cord injury. ACS Nano. 2026;20:9387-406.
118. Cui GH, Guo HD, Li H, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing. 2019;16:10.
119. Zhang L, Lin J, Xiang K, Shi T, Guo B. Omnidirectional improvement of mitochondrial health in Alzheimer’s disease by multi-targeting engineered activated neutrophil exosomes. J Control Release. 2024;376:470-87.
120. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341-5.
121. Makhijani P, Valentino TR, Manwaring-Mueller M, et al. Amyloid-β-driven Alzheimer’s disease reshapes the colonic immune system in mice. Cell Rep. 2025;44:116109.
122. Zhang S, Pan W, Ma C, et al. Dietary yam (Dioscorea opposita Thunb.) ameliorates Parkinson’s disease in mice via gut microbiota-driven mitochondrial improvement and neuroinflammation inhibition. Nutrients. 2026;18:1208.
123. Connolly MG, Fliflet AM, Ravi P, Rosu DI, Boppart MD, Rhodes JS. Exercise-induced plasma-derived extracellular vesicles increase adult hippocampal neurogenesis. Brain Research. 2025;1869:150003.
124. Xu G, Jin J, Fu Z, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduct Target Ther. 2025;10:255.
125. Wu H, Gao P, Zhou W, Chen C, Wang M, Han L. Exosome-like nanovesicles (EVNs): a comprehensive overview of their isolation, characterization and biological applications. Food Chem. 2025;495:146575.
126. Yang M, Guo J, Fang L, et al. Quality and efficiency assessment of five extracellular vesicle isolation methods using the resistive pulse sensing strategy. Anal Methods. 2024;16:5536-44.
127. Chen H, Li Q. Recent advances in scalable exosome production: challenges and innovations. Chin J Plast Reconstr Surg. 2025;7:149-63.
128. Chen Y, Xu Y, Zheng Y, et al. Harnessing 3D cultured MSC exosomes through tangential flow filtration for enhanced diabetic wound healing. Stem Cells Transl Med. 2025;14:szaf064.
129. Heikal LA, Hamdallah SI, El-Habashy SE, Ashour AA, El-Moslemany RM, El-Kamel AH. Microfluidics for separation, detection, and engineering of extracellular vesicles. Adv Drug Deliv Rev. 2026;231:115810.
130. Mukerjee N, Bhattacharya A, Maitra S, et al. Exosome isolation and characterization for advanced diagnostic and therapeutic applications. Mater Today Bio. 2025;31:101613.
131. Yousif G, Qadri S, Parray A, Akhthar N, Shuaib A, Haik Y. Exosomes derived neuronal markers: immunoaffinity isolation and characterization. Neuromolecular Med. 2022;24:339-51.
132. Yang SJ, Lin AA, Shen H, et al. Microfluidic nanomagnetically isolated neuron- and astrocyte-derived extracellular vesicles to differentiate Lewy body and Alzheimer’s disease. NPJ Biosens. 2026;3:19.
133. Dong D, Zhu T, Liao G, et al. Microfluidics-driven templating preparation of polymer vesicles with tailorable dimensions and rapid cellular internalization. Biomater Sci. 2025;13:2925-35.
134. Li H, Zhang J, Tan M, et al. Exosomes based strategies for cardiovascular diseases: opportunities and challenges. Biomaterials. 2024;308:122544.
135. Dilsiz N. A comprehensive review on recent advances in exosome isolation and characterization: toward clinical applications. Transl Oncol. 2024;50:102121.
136. Wu S, Zhao Y, Zhang Z, Zuo C, Wu H, Liu Y. The advances and applications of characterization technique for exosomes: from dynamic light scattering to super-resolution imaging technology. Photonics. 2024;11:101.
137. Zhang K, Fang J. Extracellular vesicles in drug delivery: from quality assurance to therapeutic application. Int J Nanomedicine. 2026;21:579695.
138. Li J, Wu H, Yu Z, et al. Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery. Nat Commun. 2024;15:5689.
139. Ripoll L, Zickler AM, Vader P, El Andaloussi S, Verweij FJ, van Niel G. Biology and therapeutic potential of extracellular vesicle targeting and uptake. Nat Rev Mol Cell Biol. 2026;27:358-76.
140. Fang Y, Hao X, Fang B. Extracellular vesicle therapeutics in Alzheimer’s disease: mechanisms, progress, and prospects. Extracell Vesicles Circ Nucl Acids. 2026;7:394-424.
141. De Palma ST, Hermans EC, Shamorkina TM, et al. Hypoxic preconditioning enhances the potential of mesenchymal stem cells to treat neonatal hypoxic-ischemic brain injury. Stroke. 2025;56:1872-82.
142. Iyaswamy A, Thakur A, Guan XJ, et al. Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer’s disease. Signal Transduct Target Ther. 2023;8:404.
143. Wang H, Sui H, Zheng Y, et al. Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway. Nanoscale. 2019;11:7481-96.
144. Qi Y, Guo L, Jiang Y, Shi Y, Sui H, Zhao L. Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles. Drug Deliv. 2020;27:745-55.
145. Zhao X, Ge P, Lei S, et al. An exosome-based therapeutic strategy targeting neuroinflammation in Alzheimer’s disease with berberine and palmatine. Drug Des Devel Ther. 2023;17:2401-20.
146. Jiang S, Cai G, Yang Z, et al. Biomimetic nanovesicles as a dual gene delivery system for the synergistic gene therapy of Alzheimer’s disease. ACS Nano. 2024;18:11753-68.
147. Han J, Sul JH, Lee J, et al. Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas-based epigenome editing in Alzheimer’s disease. Sci Transl Med. 2024;16:eadi4830.
148. Huang M, Zheng M, Song Q, et al. Comparative proteomics inspired self-stimulated release hydrogel reinforces the therapeutic effects of MSC-EVs on Alzheimer’s disease. Adv Mater. 2024;36:e2311420.
149. Hong Y, Zhang H, Zeng L, et al. Universal microfluidic platform for multifunctional surface modification of small extracellular vesicles. J Extracell Vesicles. 2025;14:e70215.
150. Shi X, Zhang L, Wu S, et al. A simple polydopamine-based platform for engineering extracellular vesicles with brain-targeting peptide and imaging probes to improve stroke outcome. J Extracell Vesicles. 2025;14:e70031.
151. Guan X, Zhu M, Zhu H, et al. Oral natural extracellular vesicles for biomedical applications: advances and clinical perspectives. J Adv Res. 2026;83:1105-25.
152. Rahgoshay M, Atashi A, Vaezi M, Ajorloo M, Amini-kafiabad S, Ahmadvand M. Engineered exosomes: advanced nanocarriers for targeted therapy and drug delivery in hematological malignancies. Cancer Nano. 2025;16:334.
153. Liz-Basteiro S, Sagastuy M, Perez JE, et al. Merging biological and synthetic nanoplatforms: magnetic engineering of extracellular vesicles via liposome fusion. Nano Lett. 2026;26:6190-200.
154. Huang Z, Fang Z, Ni K, et al. Peptide-engineered biomimetic nanoplatform with cell-membrane camouflage streamlines high-performance isolation and quantitation of extracellular vesicles. ACS Sens. 2025;10:5704-13.
155. Li M, Song X, Tu H, et al. A functionally tunable magnetic nanochains platform for N-glycoproteomic analysis of extracellular vesicles from ultratrace biofluids. Nat Commun. 2025;16:7646.
156. Zhang F, Li J, Gao Y, Wei Y, Wen D, Wang Z. Stimulus switches for spatial-temporal precision in therapeutic delivery systems. Nano Research. 2025;18:94907571.
157. Mao M, Komes D, Zhao S, et al. Non-invasive neuromodulation assisted by exogenous stimuli-responsive nanoplatforms for Alzheimer’s disease and Parkinson’s disease therapy. Innov Med. 2025;3:100121.
158. Wu X, Jin S, Wang Q, et al. Calcium phosphate nanoparticle-immobilized macrophage-derived extracellular vesicle nanohybrid facilitates diabetic bone regeneration. Adv Mater. 2026;38:e09410.
159. Zhang X, Liu X, Zhou Q, Yao K. Extracellular vesicle-based delivery systems for nucleic acid therapeutics. Mol Ther Nucleic Acids. 2026;37:102870.
160. Habiba UE, Sathyanarayanan R, Shamim S, et al. Intranasal administration of stem cells and their derivatives for neurological and respiratory disorders: a systematic review of human clinical trials. Front Aging Neurosci. 2026;18:1834543.
161. Chen L, Xiao B. Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection. Extracell Vesicles Circ Nucl Acids. 2026;7:441-7.
162. Ajeeb R, Clegg JR. Intrathecal delivery of macromolecules: clinical status and emerging technologies. Adv Drug Deliv Rev. 2023;199:114949.
163. Fowler MJ, Cotter JD, Knight BE, Sevick-Muraca EM, Sandberg DI, Sirianni RW. Intrathecal drug delivery in the era of nanomedicine. Adv Drug Deliv Rev. 2020;165-6:77-95.
164. Lee G, Glicksman M, Patel R, Vanjani N, Kumthekar P. DDEL-10. Retrospective review of intra-CSF drug delivery: safety and drug distribution profiles of intracerebroventricular (ICV), lumbar intrathecal (LIT), and intra-cisterna magna (ICM) injections. Neuro-Oncology. 2023;25:v103.
165. Fonseca LC, Lopes JA, Vieira J, et al. Intranasal drug delivery for treatment of Alzheimer’s disease. Drug Deliv Transl Res. 2021;11:411-25.
166. Arbabian A, Driscoll T, Li Y, Grant SC. Potential of intranasal delivery of human mesenchymal stem cells and extracellular vesicles for stroke therapy. Acta Biomater. 2026;214:23-39.
167. Kim EH, Son JP, Oh GS, et al. Clinical scale MSC-derived extracellular vesicles enhance poststroke neuroplasticity in rodents and non-human primates. J Extracell Vesicles. 2025;14:e70110.
168. Muhandiram S, Fazeli A. Does extracellular vesicle specificity truly exist? Cell Commun Signal 2026;24:125.
169. Yu Y, Xu Z, Xu L, Lu D, Tang Y, Mai H. Plant extracellular vesicles as emerging neuroprotective agents for central nervous system disorders. J Adv Res. 2026;79:879-89.
170. Iannotta D, A A, Kijas AW, Rowan AE, Wolfram J. Entry and exit of extracellular vesicles to and from the blood circulation. Nat Nanotechnol. 2024;19:13-20.
171. Li H, Yu C, Markovic T, Nestler EJ, Dong Y. Chemical strategies for brain delivery of genomic therapy. Nat Rev Chem. 2025;9:841-54.
172. Ye YL, Liu L. Engineering the future of nanomedicine: strategic approaches to extracellular vesicle-based drug administration regimens. World J Stem Cells. 2025;17:107080.
173. Lam BWS, Tan M, Gao C, et al. Extracellular vesicles administered via intrathecal injection mediate safe delivery of nucleic acids to the central nervous system for gene therapy. J Extracell Vesicles. 2025;14:e70116.
174. Xue Y, Wang C, Li H, et al. Lipid nanoparticles enhance mRNA delivery to the central nervous system upon intrathecal injection. Adv Mater. 2025;37:e2417097.
175. Zheng Y, Qin Y, He Q, et al. Enhanced delivery of oral biomacromolecules through edible plant-derived nanovehicles: exploiting the self-amplifying trancytosis feedback loop and phosphatidic acid. ACS Nano. 2026;20:1710-31.
176. Zheng Y, Wang T, Zhang J, et al. Plant-derived nanovesicles: a promising frontier in tissue repair and antiaging. J Agric Food Chem. 2025;73:13159-77.
177. Bydon M, Qu W, Moinuddin FM, et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: phase I trial. Nat Commun. 2024;15:2201.
178. Xie X, Song Q, Dai C, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial. Gen Psychiatr. 2023;36:e101143.
179. Morita Y, Izawa H, Ohga H, Sugie H, Yamamoto T, et al. Safety and clinical efficacy on intranasal administration of mesenchymal stem cell-derived secretome in patients with Alzheimer’s disease and its future prospect. Glycative Stress Res. 2024;11:103-110.
180. Luo A, Yu H, Duan T, et al. Engineered mesenchymal stem cell-derived extracellular vesicles attenuate acute glaucoma-induced neuroinflammation by reprogramming microglial polarization. Int Immunopharmacol. 2026;179:116658.
181. Zhong R, Huang W, Chen C, Zhang B, Pu J, Zhang F. Advances in neural stem cells in aging and age-related neurodegenerative diseases. Ageing Neur Dis 2025;5:2.
182. Yu Y, Ma Z, Li T, Xiao W, Li Z. Neuronal extracellular vesicles carrying APOE downregulate filament actin polymerization signaling to inhibit synapse formation in Alzheimer’s disease. J Extracell Vesicles. 2026;15:e70248.
183. Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis 2022;13:580.
